Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/hep.31890 http://scihub22266oqcxt.onion/10.1002/hep.31890 33961298!8239872!33961298     free     free     free       Hepatology 2021 ; 74 (4): 1750-1765 Nephropedia Template TP {{tp|p=33961298|t=2021. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19 |pdf=|usr=}}{{33961298}} gab.com Text Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19 JO: Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=33961298 #FOAvip BACKGROUND AND AIMS: We compared risk of acute liver injury and mortality in patients with COVID-19 and current, past, and no HBV infection. APPROACH AND RESULTS: This was a territory-wide retrospective cohort study in Hong Kong. Patients with COVID-19 between January 23, 2020, and January 1, 2021, were identified. Patients with hepatitis C or no HBsAg results were excluded. The primary outcome was mortality. Acute liver injury was defined as alanine aminotransferase or aspartate aminotransferase >/=2 x upper limit of normal (ULN; i.e., 80 U/L), with total bilirubin >/=2 x ULN (i.e., 2.2 mg/dL) and/or international normalized ratio >/=1.7. Of 5,639 patients included, 353 (6.3%) and 359 (6.4%) had current and past HBV infection, respectively. Compared to patients without known HBV exposure, current HBV-infected patients were older and more likely to have cirrhosis. Past HBV-infected patients were the oldest, and more had diabetes and cardiovascular disease. At a median follow-up of 14 (9-20) days, 138 (2.4%) patients died; acute liver injury occurred in 58 (1.2%), 8 (2.3%), and 11 (3.1%) patients with no, current, and past HBV infection, respectively. Acute liver injury (adjusted HR [aHR], 2.45; 95% CI, 1.52-3.96; P < 0.001), but not current (aHR, 1.29; 95% CI, 0.61-2.70; P = 0.507) or past (aHR, 0.90; 95% CI, 0.56-1.46; P = 0.681) HBV infection, was associated with mortality. Use of corticosteroid, antifungal, ribavirin, or lopinavir-ritonavir (adjusted OR [aOR], 2.55-5.63), but not current (aOR, 1.93; 95% CI, 0.88-4.24; P = 0.102) or past (aOR, 1.25; 95% CI, 0.62-2.55; P = 0.533) HBV infection, was associated with acute liver injury. CONCLUSION: Current or past HBV infections were not associated with more liver injury and mortality in COVID-19. Twit Text FOAVip Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19 ????Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=33961298 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33961298 #FOAvip English Wikipedia <ref>{{Cite pmid|33961298}}</ref> Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19 #MMPMID33961298 Yip TC; Wong VW; Lui GC; Chow VC; Tse YK; Hui VW; Liang LY; Chan HL; Hui DS; Wong GL Hepatology 2021[Oct]; 74 (4): 1750-1765 PMID33961298show ga BACKGROUND AND AIMS: We compared risk of acute liver injury and mortality in patients with COVID-19 and current, past, and no HBV infection. APPROACH AND RESULTS: This was a territory-wide retrospective cohort study in Hong Kong. Patients with COVID-19 between January 23, 2020, and January 1, 2021, were identified. Patients with hepatitis C or no HBsAg results were excluded. The primary outcome was mortality. Acute liver injury was defined as alanine aminotransferase or aspartate aminotransferase >/=2 x upper limit of normal (ULN; i.e., 80 U/L), with total bilirubin >/=2 x ULN (i.e., 2.2 mg/dL) and/or international normalized ratio >/=1.7. Of 5,639 patients included, 353 (6.3%) and 359 (6.4%) had current and past HBV infection, respectively. Compared to patients without known HBV exposure, current HBV-infected patients were older and more likely to have cirrhosis. Past HBV-infected patients were the oldest, and more had diabetes and cardiovascular disease. At a median follow-up of 14 (9-20) days, 138 (2.4%) patients died; acute liver injury occurred in 58 (1.2%), 8 (2.3%), and 11 (3.1%) patients with no, current, and past HBV infection, respectively. Acute liver injury (adjusted HR [aHR], 2.45; 95% CI, 1.52-3.96; P < 0.001), but not current (aHR, 1.29; 95% CI, 0.61-2.70; P = 0.507) or past (aHR, 0.90; 95% CI, 0.56-1.46; P = 0.681) HBV infection, was associated with mortality. Use of corticosteroid, antifungal, ribavirin, or lopinavir-ritonavir (adjusted OR [aOR], 2.55-5.63), but not current (aOR, 1.93; 95% CI, 0.88-4.24; P = 0.102) or past (aOR, 1.25; 95% CI, 0.62-2.55; P = 0.533) HBV infection, was associated with acute liver injury. CONCLUSION: Current or past HBV infections were not associated with more liver injury and mortality in COVID-19. |Acute Lung Injury/blood/diagnosis/*epidemiology/virology[MESH] |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Alanine Transaminase[MESH] |Aspartate Aminotransferases[MESH] |COVID-19/complications/diagnosis/*mortality/virology[MESH] |Female[MESH] |Hepatitis B Surface Antigens/isolation & purification[MESH] |Hepatitis B virus/immunology/isolation & purification[MESH] |Hepatitis B, Chronic/complications/diagnosis/*epidemiology/virology[MESH] |Hong Kong/epidemiology[MESH] |Humans[MESH] |Male[MESH] |Medical History Taking/statistics & numerical data[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Risk Assessment/statistics & numerical data[MESH]Current and Past Infections of HBV Do Not Increase Mortality in Patien(epmc).pdf DeepDyve Pubget Overpricing